<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001627'>Cardiac abnormalities</z:hpo> seen in patients with <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) are considered to be a neurally mediated process rather than a manifestation of <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In patients with SAH, myocardial injury evidenced by troponin elevation appears to predict short and long-term outcomes independently of other conventional risk </plain></SENT>
<SENT sid="2" pm="."><plain>Although incidence of <z:hpo ids='HP_0011675'>electrocardiographic changes</z:hpo>, <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and left ventricular systolic dysfunction do not independently predict the outcomes, monitoring these changes and optimizing hemodynamic status in high-grade SAH is crucial to ensure adequate cerebral perfusion and arterial oxygenation </plain></SENT>
<SENT sid="3" pm="."><plain>Novel interventions that go beyond blood pressure control, prevention of re-<z:mp ids='MP_0001914'>bleeding</z:mp>, and <z:hpo ids='HP_0002617'>aneurysm</z:hpo> obliteration should target early physiologic derangements seen in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of SAH </plain></SENT>
<SENT sid="4" pm="."><plain>The early resuscitation phase in SAH represents the greatest opportunity for impacting clinical outcome and is thus the most promising window of opportunity to demonstrate a benefit when investigating novel therapeutic strategies related to protection and modulation of cardiovascular function </plain></SENT>
<SENT sid="5" pm="."><plain>Specific measures, such as the early use of <z:chebi fb="0" ids="35530">beta-adrenergic antagonists</z:chebi>, to prevent these <z:hpo ids='HP_0001627'>cardiac abnormalities</z:hpo> and ameliorate its impact on morbidity and mortality are yet to be established </plain></SENT>
</text></document>